Horizon Technology Finance provides USD 15m venture loan facility for Emalex Biosciences.
BANKING AND CREDIT NEWS-June 10, 2020-Horizon Technology Finance provides USD 15m venture loan facility for Emalex Biosciences
(C)2020 M2 COMMUNICATIONS http://www.m2.com
Horizon Technology Finance Corporation (NASDAQ: HRZN), a specialty finance company, has partnered with biopharmaceutical company Emalex Biosciences, Inc. for USD 15 million venture loan facility to advance Emalex's development programs through clinical trials, the company said.
Emalex is a portfolio company of Paragon Biosciences, a life science innovator that creates, invests in, and builds life science companies. Paragon accelerates research and development in artificial intelligence, cell and gene therapy, synthetic biology and biopharmaceuticals.
Emalex is progressing the development of ecopipam in two Phase 2 clinical trials and has been granted Fast Track designation by the FDA for the treatment of Tourette syndrome.
Horizon Technology Finance Corporation (NASDAQ: HRZN) provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries.
Emalex Biosciences is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders.
Paragon creates, invests in and builds life science companies in artificial intelligence, cell and gene therapy, synthetic biology and biopharmaceuticals.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 Banking & Credit News (BCN)|
|Date:||Jun 10, 2020|
|Previous Article:||BNY Mellon launches FX pricing/trading engine to expand FX footprint in Singapore.|
|Next Article:||MainStreet Bank, Terra Site Constructors, donate to establish Dulles regional charitable fund.|